Compass (primary HPV cervical screening trial)

Compass randomises women attending routine cervical screening to five-yearly primary HPV testing or two-and-a-half-yearly liquid-based cytology, and is the first trial of HPV-based screening in a population already offered HPV vaccination. The registry lists 76,181 participants, a start in January 2015 and follow-up planned to 2037; it is active and no longer recruiting. The pilot phase, 4,995 women analysed from 47 Victorian practices, found high-grade precancer (CIN2+) in 1.0 to 1.2 percent of HPV-screened women against 0.1 percent with cytology, without a statistically significant rise in colposcopy referral, and its authors wrote that the findings gave initial support for HPV screening in vaccinated populations. Australia's National Cervical Screening Program moved to HPV testing every five years from December 2017.